Home > Pulmonology > NLC 2022 > Biologics in Asthma > Severe asthma in the spotlights

Severe asthma in the spotlights

Presented By
Prof. Lena Uller, Lund University, Sweden
Conference
NLC 2022
Doi
https://doi.org/10.55788/e9d97260
According to more recent insights, bronchial epithelium plays a key role in the immunopathogenesis of severe asthma. Within the affected airways, epithelial cells can be triggered by e.g. viruses, allergens, or other irritants, causing a subsequent release of pro-inflammatory cytokines, called alarmins, which subsequently induce innate and adaptive immune responses. Prof. Lena Uller (Lund University, Sweden) explained that novel biologicals targeting the epithelium cell-derived alarmins, i.e. TSLP, IL-33, and IL-25, can inhibit multiple downstream inflammatory pathways, thus offering a broad anti-inflammatory potential for patients with severe uncontrolled asthma. “In the recently published phase 3 study of tezepelumab, targeting TSLP, clinical effectiveness has been shown across both the type2 as well as the non-type2 asthma endotypes [1].” Although the most pronounced clinical improvements occurred in the type2-subpopulation, further research into anti-...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on